Preferred Label : Anti-CD19 Antibody-drug Conjugate SGN-CD19B;
NCIt synonyms : ADC SGN-CD19B;
NCIt definition : An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody
(hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine
dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking
agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic
activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets
the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen
binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released.
In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on
opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication,
leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation
of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the
immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived
cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable
conjugation of PBD to the antibody.;
Molecule name : SGN CD19B; SGN-CD19B;
NCI Metathesaurus CUI : CL504928;
Origin ID : C126377;
UMLS CUI : C4287709;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
